An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

A common artificial sweetener may trigger insulin spikes that lead to the build up of fatty plaques in the arteries, ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Can telemedicine and exercise apps improve the health of people with type 2 diabetes and coronary heart disease? A large ...

Driven by rising rates of high blood pressure, obesity, and other key risk factors, heart disease remains the leading cause ...

Blood pressure. Having both diabetes and high blood pressure dramatically increases heart disease risk. Triglycerides and low ...

More than 830 million people worldwide have diabetes—a chronic, debilitating disease. But experts say it’s possible to recover with a few proven lifestyle changes.

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...

Diabetes is a chronic disease that involves an elevated level of blood sugar. It has a high risk of causing heart disease due ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...